News - International Psoriasis Council

Displaying 1 to 2 of 55 Posts . Displaying 2 of Posts . Page of 28 . Go To Page: . Per Page: . Previous . Next . View All Sort By: .

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

IPC

Tuesday, August 20th, 2019

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

IPC

Tuesday, August 6th, 2019

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

SUBSCRIBE

Psoriasis News

the latest news from ipc, industry and others

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

Advancing Knowledge. Enhancing Care.